Skip to main content
Erschienen in: Abdominal Radiology 6/2017

02.02.2017

Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy

verfasst von: Sonja Gordic, Jad Bou Ayache, Paul Kennedy, Cecilia Besa, Mathilde Wagner, Octavia Bane, Richard L. Ehman, Edward Kim, Bachir Taouli

Erschienen in: Abdominal Radiology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of the study was to correlate tumor stiffness (TS) measured with MR elastography (MRE) with degree of tumor enhancement and necrosis on contrast-enhanced T1-weighted imaging (CE-T1WI) in hepatocellular carcinomas (HCC) treated with Yttrium-90 radioembolization (RE) or transarterial chemoembolization plus radiofrequency ablation (TACE/RFA).

Material and methods

This retrospective study was IRB-approved and the requirement for informed consent was waived. 52 patients (M/F 38/14, mean age 67 years) with HCC who underwent RE (n = 22) or TACE/RFA (n = 30) and 11 controls (M/F 6/5, mean age 64 years) with newly diagnosed untreated HCC were included. The MRI protocol included a 2D MRE sequence. TS and LS (liver stiffness) were measured on stiffness maps. Degree of tumor necrosis was assessed on subtraction images by two observers, and tumor enhancement ratios (ER) were calculated on CE-T1WI by one observer.

Results

63 HCCs (mean size 3.2 ± 1.6 cm) were evaluated. TS was significantly lower in treated vs. untreated tumors (3.9 ± 1.8 vs. 6.9 ± 3.4 kPa, p = 0.006) and also compared to LS (5.3 ± 2.2 kPa, p = 0.002). There were significant correlations between TS and each of enhancement ratios (r = 0.514, p = 0.0001), and percentage of necrosis (r = −0.540, p = 0.0001). The observed correlations were stronger in patients treated with RE (TS vs. ER, r = 0.636, TS vs. necrosis, r = −0.711, both p = 0.0001). Percentage of necrosis and T1-signal in native T1WI were significant independent predictors of TS (p = 0.0001 and 0.001, respectively).

Conclusion

TS measured with MRE shows a significant correlation with tumor enhancement and necrosis, especially in HCCs treated with RE.
Literatur
2.
Zurück zum Zitat Shields A, Reddy KR (2005) Hepatocellular carcinoma: current treatment strategies. Curr Treat Options Gastroenterol 8(6):457–466CrossRefPubMed Shields A, Reddy KR (2005) Hepatocellular carcinoma: current treatment strategies. Curr Treat Options Gastroenterol 8(6):457–466CrossRefPubMed
3.
Zurück zum Zitat Kulik LM, Atassi B, van Holsbeeck L, et al. (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94(7):572–586. doi:10.1002/jso.20609 CrossRefPubMed Kulik LM, Atassi B, van Holsbeeck L, et al. (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94(7):572–586. doi:10.​1002/​jso.​20609 CrossRefPubMed
4.
5.
Zurück zum Zitat Maddala YK, Stadheim L, Andrews JC, et al. (2004) Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10(3):449–455. doi:10.1002/lt.20099 CrossRefPubMed Maddala YK, Stadheim L, Andrews JC, et al. (2004) Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 10(3):449–455. doi:10.​1002/​lt.​20099 CrossRefPubMed
7.
Zurück zum Zitat Llovet JM, Real MI, Montana X, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739. doi:10.1016/S0140-6736(02)08649-X CrossRefPubMed Llovet JM, Real MI, Montana X, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739. doi:10.​1016/​S0140-6736(02)08649-X CrossRefPubMed
8.
Zurück zum Zitat Morimoto M, Numata K, Kondou M, et al. (2010) Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 116(23):5452–5460. doi:10.1002/cncr.25314 CrossRefPubMed Morimoto M, Numata K, Kondou M, et al. (2010) Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 116(23):5452–5460. doi:10.​1002/​cncr.​25314 CrossRefPubMed
9.
Zurück zum Zitat Kim JH, Won HJ, Shin YM, et al. (2011) Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol 18(6):1624–1629. doi:10.1245/s10434-011-1673-8 CrossRefPubMed Kim JH, Won HJ, Shin YM, et al. (2011) Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol 18(6):1624–1629. doi:10.​1245/​s10434-011-1673-8 CrossRefPubMed
11.
Zurück zum Zitat Kim S, Mannelli L, Hajdu CH, et al. (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31(2):348–355. doi:10.1002/jmri.22038 CrossRefPubMed Kim S, Mannelli L, Hajdu CH, et al. (2010) Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 31(2):348–355. doi:10.​1002/​jmri.​22038 CrossRefPubMed
13.
14.
Zurück zum Zitat Muthupillai R, Lomas DJ, Rossman PJ, et al. (1995) Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science 269(5232):1854–1857CrossRefPubMed Muthupillai R, Lomas DJ, Rossman PJ, et al. (1995) Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science 269(5232):1854–1857CrossRefPubMed
19.
Zurück zum Zitat Pepin KM, Chen J, Glaser KJ, et al. (2014) MR elastography derived shear stiffness—a new imaging biomarker for the assessment of early tumor response to chemotherapy. Magn Reson Med 71(5):1834–1840. doi:10.1002/mrm.24825 CrossRefPubMed Pepin KM, Chen J, Glaser KJ, et al. (2014) MR elastography derived shear stiffness—a new imaging biomarker for the assessment of early tumor response to chemotherapy. Magn Reson Med 71(5):1834–1840. doi:10.​1002/​mrm.​24825 CrossRefPubMed
20.
Zurück zum Zitat Wald C, Russo MW, Heimbach JK, et al. (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266(2):376–382. doi:10.1148/radiol.12121698 CrossRefPubMed Wald C, Russo MW, Heimbach JK, et al. (2013) New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 266(2):376–382. doi:10.​1148/​radiol.​12121698 CrossRefPubMed
22.
25.
Zurück zum Zitat Hennedige TP, Hallinan JT, Leung FP, et al. (2016) Comparison of magnetic resonance elastography and diffusion-weighted imaging for differentiating benign and malignant liver lesions. Eur Radiol 26(2):398–406. doi:10.1007/s00330-015-3835-8 CrossRefPubMed Hennedige TP, Hallinan JT, Leung FP, et al. (2016) Comparison of magnetic resonance elastography and diffusion-weighted imaging for differentiating benign and malignant liver lesions. Eur Radiol 26(2):398–406. doi:10.​1007/​s00330-015-3835-8 CrossRefPubMed
27.
Zurück zum Zitat Kierans AS, Elazzazi M, Braga L, et al. (2010) Thermoablative treatments for malignant liver lesions: 10-year experience of MRI appearances of treatment response. AJR Am J Roentgenol 194(2):523–529. doi:10.2214/AJR.09.2621 CrossRefPubMed Kierans AS, Elazzazi M, Braga L, et al. (2010) Thermoablative treatments for malignant liver lesions: 10-year experience of MRI appearances of treatment response. AJR Am J Roentgenol 194(2):523–529. doi:10.​2214/​AJR.​09.​2621 CrossRefPubMed
28.
Zurück zum Zitat Riaz A, Kulik L, Lewandowski RJ, et al. (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49(4):1185–1193. doi:10.1002/hep.22747 CrossRefPubMed Riaz A, Kulik L, Lewandowski RJ, et al. (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49(4):1185–1193. doi:10.​1002/​hep.​22747 CrossRefPubMed
Metadaten
Titel
Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy
verfasst von
Sonja Gordic
Jad Bou Ayache
Paul Kennedy
Cecilia Besa
Mathilde Wagner
Octavia Bane
Richard L. Ehman
Edward Kim
Bachir Taouli
Publikationsdatum
02.02.2017
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 6/2017
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1066-y

Weitere Artikel der Ausgabe 6/2017

Abdominal Radiology 6/2017 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.